Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOPTIN vs FROVA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.
Treatment of hypertension,Management of angina pectoris,Control of supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT),Off-label: Cluster headache prophylaxis, prevention of migraine, bipolar disorder (manic episodes),Off-label: Hypertrophic cardiomyopathy (obstructive)
Acute treatment of migraine with or without aura in adults
Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.
2.5 mg orally once daily; maximum 5 mg/day.
Terminal elimination half-life: 4.5-12 hours (mean 8 hours); increases with hepatic impairment or cirrhosis
Terminal elimination half-life is 26 hours. This prolonged half-life supports once-daily dosing and provides sustained headache relief.
Extensively metabolized in the liver via CYP3A4, CYP3A5, and CYP1A2 isoenzymes; major metabolite is norverapamil (active).
Hepatic via CYP1A2; primary metabolite is 5-hydroxyfrovatriptan.
Renal (70% as metabolites, 3-5% unchanged); biliary/fecal (25%)
Primarily hepatic metabolism followed by renal and fecal elimination. Approximately 62% of the dose is recovered in urine (mainly as metabolites, <10% unchanged) and 32% in feces.
90% bound to albumin
Approximately 15% bound to plasma proteins (primarily albumin).
4.5 L/kg (extensive tissue distribution, reflects high myocardial and vascular binding)
Volume of distribution (Vd) is approximately 2.4 L/kg, indicating extensive tissue distribution.
Oral: 20-35% (extensive first-pass hepatic metabolism)
Oral bioavailability is approximately 30% due to first-pass metabolism.
For Cr Cl <30 m L/min: Reduce dose by 50-75% of normal. For Cr Cl 30-50 m L/min: Start at lower end of dosing range. No specific guidelines for dialysis.
No adjustment required for GFR ≥30 m L/min; use not recommended for GFR <30 m L/min.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and monitor. Child-Pugh C: Use with caution, reduce dose by 70-80%.
Contraindicated in severe hepatic impairment (Child-Pugh C); use with caution in moderate impairment (Child-Pugh B) at reduced dose (2.5 mg every other day).
Oral: 4-8 mg/kg/day in 3-4 divided doses; maximum 360 mg/day. IV: 0.1-0.3 mg/kg/dose (max 5 mg) over 2 minutes, repeat after 30 minutes if needed.
Not approved for use in pediatric patients; safety and efficacy not established.
Start at lower end of dosing range (e.g., 40 mg orally three times daily); titrate slowly due to increased sensitivity and decreased clearance. Monitor for hypotension and bradycardia.
No specific dose adjustment, but monitor for increased sensitivity and renal function due to age-related decline.
No FDA black box warning.
Do not use in patients with ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular conditions.
Heart failure: May worsen or precipitate heart failure due to negative inotropic effects.,Hypotension: Can cause symptomatic hypotension.,Conduction abnormalities: May worsen AV block, sinus node dysfunction (risk of bradycardia).,Hepatic impairment: Reduced clearance requires dose adjustment.,Concomitant beta-blockers: Additive negative inotropic and bradycardic effects.,Digoxin: Increases digoxin levels; monitor toxicity.,Neuromuscular disorders: May exacerbate myasthenia gravis or Duchenne muscular dystrophy.,Lactation: Excreted in breast milk; caution advised.
Risk of myocardial ischemia, cerebral hemorrhage, cardiac arrhythmias; serotonin syndrome with concomitant serotonergic drugs; medication overuse headache; severe hepatic impairment.
Severe left ventricular dysfunction (ejection fraction <30%) or cardiogenic shock,Hypersensitivity to verapamil or any component of the formulation,Sick sinus syndrome or second/third-degree AV block (except with functioning pacemaker),Atrial flutter or fibrillation with accessory bypass tract (e.g., WPW syndrome) unless ventricular preexcitation is excluded,Concomitant use of IV beta-blockers (within a few hours),Severe hypotension (systolic <90 mm Hg)
Ischemic heart disease, coronary artery vasospasm, history of stroke/TIA, peripheral vascular disease, uncontrolled hypertension, hemiplegic or basilar migraine, recent MAOI use, hypersensitivity.
Grapefruit and grapefruit juice increase verapamil levels, increasing risk of toxicity. Avoid concurrent consumption. Alcohol may exacerbate hypotension and dizziness.
No significant food interactions. Grapefruit juice does not affect frovatriptan metabolism. Avoid alcohol during migraine attacks as it may worsen headache or increase drowsiness.
INSUFFICIENT DATA IN HUMANS: Animal studies show no teratogenic effects at clinically relevant doses. First trimester: case reports not indicating major malformations but risk cannot be excluded. Second/third trimester: may cause fetal bradycardia, hypotension, and intrauterine growth restriction due to placental hypoperfusion; avoid use near term due to risk of uterine atony.
Frovatriptan is contraindicated in pregnancy due to potential fetal harm. In animal studies, frovatriptan was associated with reduced fetal weights and increased incidence of fetal abnormalities at maternal toxic doses. In humans, there is no adequate data; however, triptans as a class may increase risk of preterm delivery, low birth weight, and possibly orofacial clefts when used in the first trimester. Use during first trimester: Risk category not formally assigned but should be avoided. Second and third trimesters: Avoid due to potential for uterine contractions and reduced placental perfusion. Labor and delivery: Contraindicated as it may cause uterine hypertonicity and fetal distress.
Verapamil (ISOPTIN) is excreted into human breast milk with a milk-to-plasma ratio of approximately 0.6. Limited data suggest low infant doses (estimated 0.1-1% of maternal weight-adjusted dose); caution advised, especially in preterm or ill infants.
Frovatriptan is excreted into breast milk in low amounts; the M/P ratio is approximately 2.6:1 (milk to plasma ratio). The relative infant dose is estimated at 1.5-3.5% of the maternal weight-adjusted dose. While adverse effects in breastfed infants have not been reported, caution is advised due to potential for vasoconstriction and gastrointestinal disturbances. Consider pumping and discarding milk for 24 hours after dose.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may require dose titration; no specific recommended dose adjustment, but clinical efficacy and toxicity should guide dosing; consider starting at lower doses and titrating to effect.
Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, hepatic metabolism alterations) may reduce frovatriptan exposure. However, due to contraindication and lack of safety data, no adjusted dosing is recommended. Use in pregnancy is not advised; alternative medications with better safety profiles (e.g., sumatriptan) should be considered if triptan therapy is necessary.
IV verapamil (Isoptin) can cause hypotension and bradycardia; have calcium gluconate at bedside to reverse. Avoid in patients with pre-existing heart block or systolic heart failure. Use ECG monitoring during IV administration. In atrial fibrillation, may convert to sinus rhythm but risk of ventricular preexcitation with WPW syndrome.
Frovatriptan has the longest half-life (~26 hours) among triptans, which may be beneficial for patients with prolonged migraine attacks or frequent recurrence. Onset of action is slower (~2-4 hours) compared to sumatriptan. Use with caution in patients with cardiovascular risk factors due to vasoconstrictive effects. Contraindicated within 24 hours of other triptans or ergotamine-containing medications.
Do not stop taking suddenly; may cause chest pain or irregular heartbeat.,Avoid grapefruit and grapefruit juice while taking this medication.,Do not drink alcohol; may increase dizziness and drops in blood pressure.,Take with food or milk if stomach upset occurs.,Report slow or irregular heartbeat, shortness of breath, or swelling of ankles.
Take FROVA at the first sign of a migraine headache, but it can be taken any time during an attack.,Do not exceed one tablet (2.5 mg) in a 24-hour period; if headache returns, repeat dose after at least 2 hours.,Do not take within 24 hours of another triptan or ergotamine-type medication.,Common side effects include dizziness, fatigue, tingling, and flushing. Report chest tightness, palpitations, or shortness of breath immediately.,Seek emergency care if headache worsens or is accompanied by stiff neck, fever, or vision changes.,Inform your doctor if you have heart disease, high blood pressure, liver disease, or are pregnant or breastfeeding.
No interactions on record
"Frovatriptan, a serotonin 5-HT1B/1D receptor agonist used for acute migraine, and chlorpromazine, a first-generation antipsychotic with potent dopamine D2 receptor antagonism, can lead to additive serotonin excess when co-administered due to their combined serotonergic activity. Chlorpromazine also possesses weak serotonin reuptake inhibition properties, increasing the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Additionally, chlorpromazine may antagonize the vasoconstrictive effects of triptans via alpha-adrenergic blockade, potentially reducing migraine relief efficacy."
"Frovatriptan, a triptan used for migraine, is primarily metabolized by CYP1A2. Clotrimazole, an azole antifungal, inhibits CYP1A2, thereby reducing the clearance of frovatriptan. This can lead to increased systemic exposure to frovatriptan, potentially elevating the risk of triptan-related adverse effects such as serotonin syndrome, coronary vasospasm, and hypertension."
"Coadministration of frovatriptan, a serotonin receptor agonist metabolized primarily by CYP1A2, with simeprevir, a potent CYP3A4 inhibitor and weak CYP1A2 inducer, may result in reduced clearance of simeprevir due to competitive inhibition of CYP3A4 by frovatriptan or its metabolites. This interaction can lead to increased simeprevir plasma concentrations, elevating the risk of hepatotoxicity, photosensitivity reactions, and QT prolongation. Conversely, frovatriptan exposure is not significantly altered as its metabolism via CYP1A2 is minimally affected by simeprevir."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOPTIN vs FROVA, answered by our medical review team.
ISOPTIN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.. FROVA is a Antimigraine (triptan) that works by Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOPTIN and FROVA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOPTIN is: Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.. The standard adult dose of FROVA is: 2.5 mg orally once daily; maximum 5 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOPTIN and FROVA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOPTIN is classified as Category C. INSUFFICIENT DATA IN HUMANS: Animal studies show no teratogenic effects at clinically relevant doses. First trimester: case reports not indicating major malformations but risk cann. FROVA is classified as Category C. Frovatriptan is contraindicated in pregnancy due to potential fetal harm. In animal studies, frovatriptan was associated with reduced fetal weights and increased incidence of fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.